Page 3 - Max Colao News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Max colao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Max Colao Today - Breaking & Trending Today
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights Over 250 patient start forms received by the end of the first quarter – – Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 – – Conference call to be hosted today at 5:00 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial results for the first quarter ended March 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars. “2021 started with the FDA … – Over 250 patient start forms received by the end of the first quarter – – Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 – – Conference call to be hosted today at 5:00 p.m. ET – ....
- Cash, cash equivalents, and investments of $423 million at December 31, 2020 - Victoria, BC, March 3, 2021 (T-Net) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) today issued its financial results for the fourth quarter and year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars. Over the past year, Aurinia matured into a fully-integrated biopharmaceutical company with capabilities spanning R&D, clinical, regulatory, CMC, and commercial. The recent FDA approval and immediate launch of LUPKYNIS underscores the exemplary performance and expertise of the Aurinia team, commented Peter Greenleaf, President and Chief Executive Officer of Aurinia. During 2020, we made calculated investments following the positive AURORA clinical trial results by building out a world-class commercial team, signing a major ex-US partnership with Otsuka, and ensuring we can meet future market demand for LUPKYNIS by securing our su ....
Operator Greetings, and welcome to the Aurinia Year-end 2020 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is recorded. It s now my pleasure to turn the call over to Glenn Schulman, Senior Vice President, Investor Relations. Please go ahead, sir. Glenn Schulman Senior Vice President, Corporate Communications and Investor Relations Thank you, Kevin, and good afternoon, everyone. I m pleased to welcome you to today s call discussing Aurinia s fourth quarter and year-end financial results. Joining me on the call this afternoon are Peter Greenleaf, President and CEO of Aurinia; Neil Solomons, our Chief Medical Officer; Max Colao, Chief Commercial Officer; and Joe Miller, our Chief Financial Officer. This afternoon, just after 4:00 p.m., we issued a press release announcing our financial results and recent operational highlights, which is accessible from our website at www.auriniapharma.com and has been filed on a Form 8-K ....
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death – – Cash, cash equivalents, and investments of $423 million at December 31, 2020 – – Conference call to be hosted today at 4:30 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial results for the fourth quarter … – LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death – ....
Aurinia Pharmaceuticals Inc (AUPH) Q4 2020 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.